Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ: ANIP) will be announcing earnings results tomorrow before market hours. Here’s what to expect.
ANI Pharmaceuticals beat analysts’ revenue expectations by 8.5% last quarter, reporting revenues of $190.6 million, up 44.8% year on year. It was a stunning quarter for the company, with a solid beat of analysts’ full-year EPS guidance estimates and full-year revenue guidance exceeding analysts’ expectations.
Is ANI Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting ANI Pharmaceuticals’s revenue to grow 30.7% year on year to $179.6 million, improving from the 28.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.38 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. ANI Pharmaceuticals has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 5.7% on average.
Looking at ANI Pharmaceuticals’s peers in the generic pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 5.5%, missing analysts’ expectations by 3.4%, and Amphastar Pharmaceuticals reported flat revenue, falling short of estimates by 2%. Amneal traded down 2.4% following the results.
Read our full analysis of Amneal’s results here and Amphastar Pharmaceuticals’s results here.
Investors in the generic pharmaceuticals segment have had steady hands going into earnings, with share prices flat over the last month. ANI Pharmaceuticals is up 8.8% during the same time and is heading into earnings with an average analyst price target of $81.88 (compared to the current share price of $71.82).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
